Loading candles…
Supriya Lifescience Ltd., headquartered in Mumbai, India, was initially established as a partnership in 1987 and later incorporated as a public limited company in 2008. The company operates in the pharmaceutical industry, specializing in the manufacturing and export of Active Pharmaceutical Ingredients (APIs). Its portfolio includes 38 APIs focused on therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic, and anti-allergic. Supriya Lifescience follows a backward-integrated business model supported by a specialized manufacturing facility and dedicated research and development capabilities. The company serves markets across India and exports to over 120 countries globally. It is recognized as a niche player within the global regulated life science sector.
| Date |
|---|
| Audited Results - Q4 & FY26 | Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2026 And Recommend Dividend, If Any, On The Equity Shares Of The Company Fo… | 27 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 9 Feb 2026 |
| Unaudited Results - Q2 & FY25 | In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this to inform you that a meeting of the Board of Dire… | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 13 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 27 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.